Lifearc and Provincial Health Services Authority (PHSA) have presented 7-morpholino-l,6-naphthyridin-5-yl derivatives acting as DNA-dependent protein kinase (DNA-PK) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.

Blueprint Medicines Corp. has divulged new EGFR mutant inhibitors, particularly EGFR L858R mutant and EGFR del746-750 mutant, reported to be useful for the treatment of non-small-cell lung cancer.

Latigo Biotherapeutics Inc. and Lieber Institute Inc. have synthesized new methyl-substituted pyridine and pyridazine compounds acting as sodium channel protein type 10 subunit α (Nav1.8) channel blockers reported to be useful for the treatment of pain, arthritis, atherosclerosis, irritable bowel syndrome, cancer and psychiatric, respiratory and neurological disorders, among other disorders.

Dice Molecules SV LLC has divulged new integrin αv/β1 and/or integrin αv/β6 antagonists reported to be useful for the treatment of fibrosis, rheumatoid arthritis, diabetic nephropathy, nonalcoholic steatohepatitis, focal segmental glomerulosclerosis, primary biliary cholangitis and cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new heterocyclic RAF kinase and/or Ras GTPases inhibitors reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has identified new histone deacetylase 1 (HDAC1) and/or HDAC3 inhibitors reported to be useful for the treatment of cancer.

Leitat Technological Center has patented 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine derivatives acting as sigma non-opioid intracellular receptor 1 (SIGMAR1) and sigma intracellular receptor 2 (TMEM97) ligands reported to be useful for the treatment of pain, hyperalgesia, depression, anxiety and attention deficit hyperactivity disorder (ADHD).

Galecto Biotech AB has divulged new galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.

Akita University and Tohoku University have described curcumin derivatives acting as β-catenin (CTNNB1) and NF-κB activation inhibitors reported to be useful for the treatment of cancer.